Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01479439 · ClinicalTrials.gov registry record · Phase 2
Losartan to Reverse Sickle Nephropathy
A Phase 2 study, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01479439 is a Phase 2 study that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 36 participants.
The verdict
NCT01479439, a Phase 2 study, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
Sickle cell disease causes kidney damage with increasing age, leading to chronic kidney disease and renal failure in nearly one third of patients with sickle cell disease. Currently, there is no treatment for sickle cell related kidney disease.
Interventions
- DRUG Losartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01479439
The ClinicalTrials.gov registry entry for NCT01479439 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Losartan is the first listed.
NCT01479439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01479439 about?
NCT01479439 is a clinical study titled "Losartan to Reverse Sickle Nephropathy". Sickle cell disease causes kidney damage with increasing age, leading to chronic kidney disease and renal failure in nearly one third of patients with sickle cell disease. Currently, there is no treatment for sickle cell related kidney disease.
What is the current status of trial NCT01479439?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2012-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01479439?
The interventions under investigation include: Losartan (DRUG).
Who is sponsoring clinical trial NCT01479439?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.